Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

News

Biden Economic Adviser Brian Deese Said U.S. is Strong Enough to Avoid a Recession

-FT https://www.ft.com/content/ddcd309f-2aa3-4a60-98bb-95ff0f495439

byCharles Gross

October 23, 2022

1 minute read

-FT

https://www.ft.com/content/ddcd309f-2aa3-4a60-98bb-95ff0f495439

Goldman Sachs Maintains Neutral on CyberArk Software, Raises Price Target to $190

By Benzinga Newsdesk

November 5, 9:08 AM

Goldman Sachs maintains CyberArk Software (NASDAQ:CYBR) with a Neutral and raises the price target from $166 to $190.

CYBR

Rockwell Automation Q4 Adj. EPS $2.33 Beats $2.17 Estimate, Sales $1.81B Miss $1.91B Estimate

By Benzinga Newsdesk

November 2, 7:04 AM

Rockwell Automation (NYSE:ROK) reported quarterly earnings of $2.33 per share which beat the analyst consensus estimate of $2.17 by 7.37 percent. This is a 24.6 percent increase over earnings of $1.87 per share from the

ROK

Goldman Sachs Initiates Coverage On Invitae with Neutral Rating, Announces Price Target of $33

By Benzinga Newsdesk

June 3, 6:34 AM

Goldman Sachs analyst Matthew Sykes initiates coverage on Invitae (NYSE:NVTA) with a Neutral rating and announces Price Target of $33.

NVTA

HC Wainwright Sees ‘Buying Opportunity’ For This COVID-19 Antibody Stock After Sell-Off

By Vandana Singh

November 30, 4:11 PM

H.C. Wainwright recommends using the selloff today for Regeneron Pharmaceuticals Inc (NASDAQ: REGN) as a buying opportunity.

REGN

Biden Economic Adviser Brian Deese Said U.S. is Strong Enough to Avoid a Recession

Related Posts

Goldman Sachs Maintains Neutral on CyberArk Software, Raises Price Target to $190

Rockwell Automation Q4 Adj. EPS $2.33 Beats $2.17 Estimate, Sales $1.81B Miss $1.91B Estimate

Goldman Sachs Initiates Coverage On Invitae with Neutral Rating, Announces Price Target of $33

HC Wainwright Sees ‘Buying Opportunity’ For This COVID-19 Antibody Stock After Sell-Off